Abstract
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced for palliative treatment of peritoneal cancer (PC) and is currently tested also in the neoadjuvant and prophylactic setting. The aim was therefore to compare safety and tolerance of staging laparoscopy with or without PIPAC.
Highlights
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced for palliative treatment of peritoneal cancer (PC) and is currently tested in the neoadjuvant and prophylactic setting
PIPAC procedures took a median of 35 min (IQR: 25-67) longer
Objective clinical response was reported in the palliative setting in 62–88% of patients with ovarian cancer, between 50% and 91% for gastric cancer and 71–86% for colorectal cancer [8]
Summary
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced for palliative treatment of peritoneal cancer (PC) and is currently tested in the neoadjuvant and prophylactic setting. The aim was to compare safety and tolerance of staging laparoscopy with or without PIPAC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
